Skip to main content
Erschienen in: hautnah 2/2017

01.05.2017 | Fallbericht

Therapieresistentes Erysipel?

verfasst von: Dr. Emel Türkay, Nina Häring, Robert Strohal

Erschienen in: hautnah | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Wir präsentieren den Fall eines 39-jährigen männlichen Patienten mit therapieresistenten Hautveränderungen im Bereich des M. pectoralis major rechts. Trotz unauffälliger Hautbiopsie wurde vor allem wegen einer B‑Symptomatik eine weiterführende radiologische Abklärung durchgeführt. Schließlich konnte mithilfe einer sonographisch gezielten Stanzbiopsie der radiologisch dargestellten Raumforderung die Diagnose eines primär systemischen großzelligen anaplastischen Lymphoms gestellt werden. Nach Komplettierung der Staging-Untersuchungen wurde eine kombinierte Chemotherapie nach CHOP-Schema eingeleitet, worunter eine komplette Remission erzielt werden konnte. Bei den Nachsorgeuntersuchungen wurde bis heute kein Hinweis auf ein Rezidiv festgestellt.
Literatur
1.
Zurück zum Zitat Stein, all (1985) The expression of Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4):848PubMed Stein, all (1985) The expression of Hodgkin disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66(4):848PubMed
2.
Zurück zum Zitat Stein H, Foss HD, Dürkop H et al (2000) CD30(1) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96(12):3681–3695PubMed Stein H, Foss HD, Dürkop H et al (2000) CD30(1) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96(12):3681–3695PubMed
3.
Zurück zum Zitat Hapgood G, Savage KJ, Centre for Lymphoid Cancer, Department of Medical Oncology, British Columbia Cancer Agency and Division of Medical Oncology, Department of Medicine, University of British Columbia (2015) The biology and management of systemic anaplastic large cell lymphoma. Blood 126:17–25. doi:10.1182/blood-2014-10-567461 CrossRefPubMed Hapgood G, Savage KJ, Centre for Lymphoid Cancer, Department of Medical Oncology, British Columbia Cancer Agency and Division of Medical Oncology, Department of Medicine, University of British Columbia (2015) The biology and management of systemic anaplastic large cell lymphoma. Blood 126:17–25. doi:10.​1182/​blood-2014-10-567461 CrossRefPubMed
4.
Zurück zum Zitat Elaine S, Jaffe MD, Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute (2001) Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 14(3):219CrossRef Elaine S, Jaffe MD, Laboratory of Pathology, Division of Clinical Sciences, National Cancer Institute (2001) Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 14(3):219CrossRef
6.
Zurück zum Zitat Kadin ME (2009) Current management of primary cutaneous CD30+ T‑cell lymphoproliferative disorders. Oncology 23:1158–1164PubMed Kadin ME (2009) Current management of primary cutaneous CD30+ T‑cell lymphoproliferative disorders. Oncology 23:1158–1164PubMed
7.
Zurück zum Zitat Weaver J, Mahindra AK, Pohlman B et al (2010) Non-mycosis fungoides cutaneous T‑cell lymphoma: reclassification according to the WHO-EORTC classification. J Cutan Pathol 37:516CrossRefPubMed Weaver J, Mahindra AK, Pohlman B et al (2010) Non-mycosis fungoides cutaneous T‑cell lymphoma: reclassification according to the WHO-EORTC classification. J Cutan Pathol 37:516CrossRefPubMed
8.
Zurück zum Zitat Yang S, Khera P, Wahlgren C et al (2011) Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 12:203CrossRefPubMed Yang S, Khera P, Wahlgren C et al (2011) Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 12:203CrossRefPubMed
9.
Zurück zum Zitat Savage KJ, Harris NL, Vose JM et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T‑cell lymphoma, not otherwise specified: report from the International Peripheral T‑Cell Lymphoma Project. Blood 111:5496CrossRefPubMed Savage KJ, Harris NL, Vose JM et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T‑cell lymphoma, not otherwise specified: report from the International Peripheral T‑Cell Lymphoma Project. Blood 111:5496CrossRefPubMed
10.
Zurück zum Zitat Kinney MC, Higgins RA, Medina EA (2011) Anaplastic large cell lymphoma: twenty-five years of dis-covery. Arch Pathol Lab Med 135:19–43PubMed Kinney MC, Higgins RA, Medina EA (2011) Anaplastic large cell lymphoma: twenty-five years of dis-covery. Arch Pathol Lab Med 135:19–43PubMed
11.
Zurück zum Zitat Zeng FH, Li YH, Zeng J, Rao HL, Xia ZJ, Sun XF, Huang HQ, Lin TY, Jiang WQ, Guan ZZ (2009) Clinical analysis of primary systemic anaplastic large cell lymphoma. Chin J Cancer 28(1):49–53 Zeng FH, Li YH, Zeng J, Rao HL, Xia ZJ, Sun XF, Huang HQ, Lin TY, Jiang WQ, Guan ZZ (2009) Clinical analysis of primary systemic anaplastic large cell lymphoma. Chin J Cancer 28(1):49–53
12.
Zurück zum Zitat Toby TA, Khan D, Hall GW, Graham P, Collins (2014) Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol 93(6):455. doi:10.1111/ejh.12360 CrossRef Toby TA, Khan D, Hall GW, Graham P, Collins (2014) Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease. Eur J Haematol 93(6):455. doi:10.​1111/​ejh.​12360 CrossRef
13.
Zurück zum Zitat Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A (2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7(19):24. doi:10.1186/1756-8722-7-24 CrossRefPubMedPubMedCentral Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, Huebner D, Levine P, Grove L, Forero-Torres A (2014) Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol 7(19):24. doi:10.​1186/​1756-8722-7-24 CrossRefPubMedPubMedCentral
Metadaten
Titel
Therapieresistentes Erysipel?
verfasst von
Dr. Emel Türkay
Nina Häring
Robert Strohal
Publikationsdatum
01.05.2017
Verlag
Springer Vienna
Erschienen in
hautnah / Ausgabe 2/2017
Print ISSN: 1866-2250
Elektronische ISSN: 2192-6484
DOI
https://doi.org/10.1007/s12326-017-0229-5

Weitere Artikel der Ausgabe 2/2017

hautnah 2/2017 Zur Ausgabe